This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence Built on Evidence1-4
Adapted from Turner NC et al., 2018 supplementary appendix
Adapted from Turner NC et al., 2018 supplementary appendix
In the PALOMA-3 trial, neutropenia was the most frequently reported AE of any grade occurring in 84.1% of patients treated with palbociclib + fulvestrant (n=345). Febrile neutropenia occurred in ~1% of these patients.3
Neutropenia can often be managed with IBRANCE dose interruptions/delays or dose reductions.4
Permanent discontinuation of IBRANCE® due to any adverse event was necessary in 5.2% of patients across the PALOMA trials.4
*based on pooled data from 872 patients who received palbociclib in combination with endocrine therapy (N=527 in combination with letrozole and N=345 in combination with fulvestrant) in randomised clinical studies in HR+ HER2- mBC.
Treatment-Emergent Adverse Event Reported in ≥10% of patients in the palbociclib plus fulvestrant arm3
Please refer to the Ibrance SmPC for full safety profile information and guidance on dose modifications and the management of treatment related AEs.
Adapted from Turner NC, et al. 2018, supplementary appendix.3
In a population of pre-/peri- and post-menopausal women with HR+/HER2- advanced or metastatic breast cancer who had progressed on previous ET therapy.3
Grading according to CTCAE 4.0.4
PTs are listed according to MedDRA 17.1:4
*Neutropenia includes neutropenia and neutrophil count decreased; †Leukopenia includes leukopenia and white blood cell count decreased;‡Infections includes any PT under the system organ class infections and infestations; §Anaemia includes the PTs anaemia, haematocrit decreased, and haemoglobin decreased; ¶Stomatitis includes aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort, oropharyngeal pain, and stomatitis; **Thrombocytopenia includes platelet count decreased and thrombocytopenia; ††Rash includes dermatitis, dermatitis acneiform, rash, rash erythematous, rash maculopapular, rash popular, rash pruritic, and toxic skin eruption.
For full safety profile information, please refer to the IBRANCE SmPC.
AE : Adverse Event, AI: Aromatase Inhibitor, AST ; aspartate aminotransferase, CTCAE : Common Terminology Criteria for Adverse Events, ET : endocrine therapy, HR+/ HER2- : Hormone Receptor‑Positive/ Human Epidermal Growth Factor Receptor 2-Negative, LHRH : Luteinising Hormone-Releasing Hormone, MedDRA : Medical Disctionary for Regulatory Activities, PT : Preferred Term, SmPC : Summary Of Product Characteristics.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021